Sanofi announced an extension of the expiration date for its tender offer to acquire all outstanding shares of Blueprint Medicines Corporation common stock. The new expiration date was set for 5:00 p.m. EDST on July 17, 2025.
As of the announcement, 45.85% of Blueprint shares had been validly tendered in the offer. The terms of the offer remain unchanged, with shareholders set to receive $129.00 per share in cash, plus one non-transferable contractual contingent right per share.
These contingent rights represent the potential to receive up to $6 in additional payments based on future development and regulatory milestones for BLU-808. This extension is a routine step in the acquisition process, allowing additional time for shareholders to tender their shares.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.